Chris Gibson

Freed from the shackles of daily operation, and with a few weeks of decent sleep under my belt, I found the time to sit down and write a thing about TechBio. Take a read and then tell me if you are an 'AI maximalist' or an 'AI minimalist'... (yes, that's a leading question). linkedin.com/pulse/wrong-be… via @LinkedIn

Joining the @PacBio board. In the AI era, data quality is the moat. Doesn’t matter how good your model is if your training data is noise. I believe PacBio makes the best sequencing data on the planet. Time to help them turn that into a category-defining advantage. 🧬 investor.pacificbiosciences.com/news-releases/…

Seems fine…

@celinehalioua Ummm. I have pictorial evidence to the contrary.

i am not a karaoke person *at all* yet somehow the company ive founded has definitively turned into a Karaoke Company...

@Ronalfa @iScienceLuvr Claude is pretty amazing. Spending more time there than with any previous LLM…

@iScienceLuvr Hangin with Claude all day so far.

"oh, it's valentine's day? i totally forgot i was too busy grinding on my B2B SaaS startup" - half the founders on Twitter

Autonomous delivery still rusty…

@Ronalfa Like this? I think it’s awesome. More people working on problems that matter is good.

people literally starting the same companies over and over again.

@nalidoust Cool. This was the founding thesis of recursion 12 years ago and is how we got our program in phase 2 for FAP. It works well in the right cellular contexts.

Our analysis is a recipe for how it can be done when you have access to perturbative data like Tahoe-100M.

What if we scored drugs not by whether they kill diseased cells, but by whether they push them back to normal? New blog post from Tahoe: we applied cell-state reversal to colorectal cancer using Tahoe-100M, and the results are striking.

@loyalfordogs @age1vc @BaillieGifford Let’s go @celinehalioua and team! These two are counting on you!

We’re excited to share we’ve raised $100M in Series C funding, bringing our total investment to over $250M. Led by @age1vc with participation from @BaillieGifford and existing investors, this funding will help us move from late-stage development to market readiness for LOY-002.

Fantastic work! So excited to watch this vision grow wings! 👏👏👏

Love this.

@kulesatony Absolutely. And you will be willing to put your shoulder behind the best answer to the problem, even if that efforts faces higher hurdles and the chances of succeeding are low.

Something I learned from Doug Lauffenburger — If you find yourself driven by competition, it’s a sign that the stakes are too small. For the problems that really matter, you’ll cheer on the competition.

Adding this to a growing list of signals that suggest not that we are necessarily at some tipping point in the world today, but that we seem to be accelerating in that direction in a way that feels less and less recoverable except by extraordinary means. It seems to me AI isn’t the driver of our trajectory, but simply an accelerant. After all, these tools are trained on the collective output us humans.

Go hawks!

@ElliotHershberg Congrats @ElliotHershberg and family!

Welcome to the world, Rosalind Hershberg 🧬💜

@devahaz Outlier weirdos. I love that - and so true!

Excellent essay on venture backed startup path. Outlier weirdos taking high risk to pursue crazy ideas has largely given way to credentialed optimizers executing on a best practices playbooks with lots of money early on and secure fallback options.

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence –  to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here: ir.recursion.com/news-releases/…

@AntounNabhan But if you can, and you do, then you get to experience a feeling unlike almost any other. Knowing you helped build something with a shot at helping lots of people. Even a taste of that feeling at phase 2 success is incredible.

@RecursionChris It’s absolutely a noble pursuit. However, if you can’t recruit/retain great management, you typically do not get to see your inventions turn into working medicines. The other point is that many (most?) entrepreneurs in biotech don’t have the facts about these tradeoffs up-front.

More on the theme. Entrepreneurship in biotech is financially completely irrational for the entrepreneurs. You make far more chugging along at Sr. Director level for 10 years in a big Pharma, collecting RSUs, than the average private-co CEO/CFO/CSO. (CMO may be exception).

@drrichjlaw Not the coolest companies. They are rarely recycled management on well understood ideas. Just the follower cos…

@RecursionChris Would be fair to say that most VC backed companies these days are recycled management for well understood ideas. Experienced management lowers the execution risk. But VCs massively under-indexed on fast-follower value destruction risk, especially adding in China. Innovation wins!

“When the institutions are optimized to fund the legible thing and the individuals are optimized to build the legible thing, the identity of the founder itself fades. Being a founder used to carry with it the implication that you had seen something others hadn’t, that you were willing to be wrong in public about an unlikely future you believed in, and take a risk of banging your head against a wall with high career risk for a long time.” Definitely seeing this… however, I (hope) and believe there will be a big wave of mission-driven companies, even with millennial founders, as people realize now that the pendulum has swung how thoroughly exhausting it is to build something you don’t feel good about.